Loading organizations...
Loading organizations...
Novel targeted cancer therapeutics focused on apoptosis and autophagy.
Gemin X Pharmaceuticals has raised $24.0M across 2 funding rounds.
Gemin X Pharmaceuticals has raised $24.0M in total across 2 funding rounds.
Gemin X Pharmaceuticals has raised $24.0M in total across 2 funding rounds.
Gemin X Pharmaceuticals's investors include Caxton Advantage Life Sciences Fund, Sanderling Ventures.
Gemin X Pharmaceuticals has raised $24.0M across 2 funding rounds. Most recently, it raised $8.0M Series E in August 2010.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 5, 2010 | $8.0M Series E | Caxton Advantage Life Sciences Fund, Sanderling Ventures | |
| Apr 20, 2010 | $16.0M Series D | Caxton Advantage Life Sciences Fund, Sanderling Ventures |